SynDevRx, Inc. Competitors

FLAG Therapeutics Inc., headquartered in Raleigh, North Carolina, is an early-stage oncology company focused on the development of therapies based on two novel classes of small molecule, water-soluble drugs. In vivo studies suggest that both classes of compounds, antiangiogenic/ anti-tubulin (AA/AT) compounds and folate-targeted anti-cancer (FTAC) compounds, hold the potential to treat multiple cancer types with greater safety and efficacy than conventional therapies. FLAG Therapeutics has obtained exclusive worldwide rights to these compounds from Duquesne University.

Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs with low and manageable toxicity for various cancers. And within much shorter timeframes compared to traditional chemotherapy development. Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. Phase II trials are scheduled for Q3 2017.

Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I kinase inhibitors. Arog is poised to enroll patients in pivotal, randomized Phase III trials of its lead molecule, crenolanib. In addition to the four clinical trials it has already completed, Arog is also engaged in three ongoing Phase II clinical trials.